Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01859312 · ClinicalTrials.gov registry record · Phase 2

Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia

A Phase 2 study of Adrenal Insufficiency and Congenital Adrenal Hyperplasia (CAH), sponsored by National Institutes of Health Clinical Center (CC).

Completed
Registry status
Phase 2
Development phase
8
Enrollment target
1
Study location

NCT01859312: Completed Phase 2 study of Adrenal Insufficiency and Congenital Adrenal Hyperplasia (CAH), sponsored by National Institutes of Health Clinical Center (CC).

NCT01859312 is a Phase 2 study of Adrenal Insufficiency and Congenital Adrenal Hyperplasia (CAH) that has completed, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 8 participants, below the 3,065-participant average among 5 other Adrenal Insufficiency trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01859312, a Phase 2 study of Adrenal Insufficiency and Congenital Adrenal Hyperplasia (CAH), has completed, sponsored by National Institutes of Health Clinical Center (CC).

COMPLETED
Registry status
Phase 2
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

Background: * Congenital adrenal hyperplasia (CAH) is a genetic disorder of the adrenal gland. The adrenal gland is located in the abdomen and produces small amounts of hormones such as cortisol, aldosterone, and androgen. These hormones help control blood pressure, protect the body, and maintain good health, especially during development. People with CAH do not make enough cortisol and aldosterone, and make too much androgen. This can lead to serious medical problems. The standard treatment is to take pills that mimic the effects of cortisol and aldosterone. However, treatment with pills can have long-term side effects because of the higher doses needed, and may not work well for some people. * A possible new treatment for CAH is to use a pump to deliver cortisol under the skin. Similar pumps are often used to give insulin to people with diabetes. Researchers think that a cortisol pump might be able to help the body use the cortisol more effectively than taking pills. They want to compare the results of a cortisol pump and standard pill treatments for CAH. Objectives: \- To compare the effectiveness of a cortisol pump with standard cortisol pill therapy for CAH. Eligibility: \- Men and women at least 18 years of age who have CAH (see more details in Eligibility section below). Design: * This study will involve four inpatient hospital stays at the National Institutes of Health in Bethesda, MD over 6 months (spaced 2 months apart). The first and last stays will last about 5 days. The second and third stays will last about 3 days. * Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. * At the first study visit, participants will provide regular blood and urine samples. They will also have imaging studies. These studies will look at the bones, fat, and muscles in the abdomen and pelvis. * Participants will receive a cortisol pump during the first visit. They will be shown how to use the pump. They wi

Primary Outcome

17-OHP (17-hydroxyprogesterone) is a laboratory blood test to test for congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency

Interventions

  • DRUG Hydrocortisone (Solucortef)
  • DEVICE Insulin pump (Medtronic)

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2013-05-06
Est. Completion 2016-12-02
Phase Phase 2

What the finished NCT01859312 record still lists

NCT01859312 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 3,065-participant average among 5 other Adrenal Insufficiency trials with a reported enrollment target (100% lower).

The record links to 3 conditions, with Adrenal Insufficiency appearing as the primary indexed condition, and to 2 interventions - of which Hydrocortisone (Solucortef) is the first listed.

NCT01859312 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT01859312 about?

NCT01859312 is a clinical study titled "Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia". Background: * Congenital adrenal hyperplasia (CAH) is a genetic disorder of the adrenal gland. The adrenal gland is located in the abdomen and produces small amounts of hormones such as cortisol, aldosterone, and androgen. These hormones help control blood pressure, protect the body, and maintain g...

What is the current status of trial NCT01859312?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2013-05-06. Estimated completion is 2016-12-02.

What conditions does trial NCT01859312 study?

This clinical trial studies the following conditions: Adrenal Insufficiency, Congenital Adrenal Hyperplasia (CAH), Excess Androgen.

What interventions are being tested in trial NCT01859312?

The interventions under investigation include: Hydrocortisone (Solucortef) (DRUG), Insulin pump (Medtronic) (DEVICE).

Who is sponsoring clinical trial NCT01859312?

This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01859312 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Adrenal Insufficiency

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01859312, the US trial registry maintained by the National Library of Medicine. NCT01859312 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.